PATENT CLAIM ANALYSIS

Application Number: 15901439
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["514", "397000"]

Abstract:
The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.

Claim (Index 199):
The method of  claim 198 , wherein the leukemia is acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic neutrophilic leukemia, acute undifferentiated leukemia, anaplastic large-cell lymphoma, prolymphocytic leukemia, juvenile myelomonocytic leukemia, adult T-cell acute lymphocytic leukemia, acute myeloid leukemia with trilineage myelodysplasia, mixed lineage leukemia, eosinophilic leukemia, and/or mantle cell lymphoma.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 88.0
- Lexical Diversity: 1.58333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15581736', '14053011', '15101240', '14820434', '14671613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7907678786729919
- 35 USC 102 Novelty (BERT): 0.5364372344079603
- Combined Prediction Score: 0.7653348142464887
- Mean Citation Score: 348.025778
- Max Citation Score: 372.31412
- Similarity Product: 312.98418661456816

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test